Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cambridge Leads National Drug Trial to Prevent Deaths After Covid-19 Patients Leave Hospital
Details : HEAL-COVID will enrol patients when they are discharged from hospital, following their first admission for COVID-19. They will be randomised and given one of two drugs – apixaban and atorvastatin – and their progress tracked.
Product Name : Eliquis
Product Type : HPAPI
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
